| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
24.01.2011 US 201161435510 P
|
| (43) |
Date of publication of application: |
|
04.12.2013 Bulletin 2013/49 |
| (73) |
Proprietors: |
|
- Gilead Sciences, Inc.
Foster City, CA 94404 (US)
- National Research Council of Canada
Ottawa, Ontario K1A 0R6 (CA)
|
|
| (72) |
Inventors: |
|
- TIKHOMIROV, Ilia Alexandre
Toronto
Ontario M8Z 1P5 (CA)
- JARAMILLO, Maria L.
Beaconsfield
Québec H9W 2M2 (CA)
- O'CONNOR-MCCOURT, Maureen D.
Beaconsfield
Québec H9W 1P2 (CA)
- SULEA, Traian
Kirkland
Québec H9J 3A2 (CA)
- GILBERT, Renald
Montreal
Québec H4V 2B4 (CA)
- GAILLET, Bruno
Sainte Julienne
Québec J0K 2T0 (CA)
- BAARDSNES, Jason
Montreal
Québec H3K 1N8 (CA)
- BANVILLE, Myriam
Laval
Québec H7X 3K4 (CA)
- GROTHE, Suzanne
Montreal
Québec H4H 1X8 (CA)
|
| (74) |
Representative: Greaves Brewster LLP |
|
Copa House
Station Road
Cheddar, Somerset BS27 3AH
Cheddar, Somerset BS27 3AH (GB) |
| (56) |
References cited: :
WO-A1-96/40210
|
WO-A2-2008/104183
|
|
| |
|
|
- Ilia A. Tikhomirov ET AL: "Binding Binding Properties of Epidermal Growth Factor Receptor
(EGFR) Targeted Monoclonal Antibodies: Factors Contributing to Differences in Observed
Clinical Profiles (A36)", AACR Cancer Clinical Trials and Personalized Medicine, 1
August 2008 (2008-08-01), XP055197559, Retrieved from the Internet: URL:http://ymbiosciences.q4web.com/files/d
oc_downloads/Nimotuzumab/poster_nimo_AACR_ Translational_Med_2008_v001_q194wg.pdf
[retrieved on 2015-06-23]
- MELARKODE RAMAKRISHNAN ET AL: "Nimotuzumab, a promising therapeutic monoclonal for
treatment of tumors of epithelial origin", MABS, 1 January 2009 (2009-01-01), pages
41-48, XP055173443,
- A. TALAVERA ET AL: "Nimotuzumab, an Antitumor Antibody that Targets the Epidermal
Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor
Conformation", CANCER RESEARCH, vol. 69, no. 14, 15 July 2009 (2009-07-15) , pages
5851-5859, XP055197598, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-4518
- ARLHEE DIAZ MIQUELI ET AL: "Biological Activity In Vitro of Anti-Epidermal Growth
Factor Receptor Monoclonal Antibodies with Different Affinities", HYBRIDOMA, vol.
26, no. 6, 1 December 2007 (2007-12-01), pages 423-432, XP055197602, ISSN: 1554-0014,
DOI: 10.1089/hyb.2007.0516
- CROMBET T ET AL: "Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal
Antibody h-R3 in Combination with Advanced Head and Neck Cancer Patients", JOURNAL
OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 22, no. 9, 1
May 2004 (2004-05-01), pages 1646-1654, XP008131473, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.03.089
- STEPHEN I. RUDNICK ET AL: "Affinity and Avidity in Antibody-Based Tumor Targeting",
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 24, no. 2, 1 April 2009 (2009-04-01),
pages 155-161, XP055069540, ISSN: 1084-9785, DOI: 10.1089/cbr.2009.0627
- MASAYUKI ODA ET AL: "Reevaluation of stoichiometry and affinity/avidity in interactions
between anti-hapten antibodies and mono- or multi-valent antigens", MOLECULAR IMMUNOLOGY,
vol. 37, no. 18, 1 December 2000 (2000-12-01), pages 1111-1122, XP055197715, ISSN:
0161-5890, DOI: 10.1016/S0161-5890(01)00028-1
- GRETA GARRIDO ET AL: "Bivalent binding by intermediate affinity of nimotuzumab: A
contribution to explain antibody clinical profile", CANCER BIOLOGY & THERAPY, vol.
11, no. 4, 15 February 2011 (2011-02-15), pages 373-382, XP055197571, ISSN: 1538-4047,
DOI: 10.4161/cbt.11.4.14097
- BOLAND, W ET AL.: 'The Emerging Role OfNimotuzumab In The Treatment Of Non-Small Cell
Lung Cancer.' BIOLOGICS vol. 4, 09 November 2010, pages 289 - 298, XP055115351
- DONALDSON, J. M. ET AL.: 'Design And Development Of Masked Therapeutic Antibodies
To Limit Off- Target Effects: Application To Anti-EGFR Antibodies.' CANCER BIOL THER
vol. 8, November 2009, pages 2147 - 2152, XP009135774
|
|
